Viatris Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 03/27/2024
Viatris Inc Stock Forecast and Price Target
The average price target for Viatris Inc's stock of $12.00 recently provided by five leading analysts would represent a 0.25% upside from its last closing price if reached. This potential increase is based on a high estimate of $14.00 and a low estimate of $11.00. You may be interested in rivals even if you aren't interested in Viatris Inc stock.
0.25% Upside
Viatris Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Viatris Inc's Price has fallen from $15.96 to $0.00 – a 100.00% decrease. For next year, analysts predict Fair Value of $13.90, which would mean an increase of 100.00%. Over the next seven years, experts predict that Viatris Inc's Fair Value will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$734.37 | Buy/Sell | $636.99 | 10.71% |
JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$161.23 | Buy/Sell | $174.55 | 5.44% |
MRK Stock Forecast | Merck | Outperform |
2
|
$122.77 | Buy/Sell | $130.51 | 9.96% |
PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.37 | Buy/Sell | $32.87 | 10.82% |
BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$54.36 | Buy/Sell | $58.15 | 1.18% |
Viatris Inc Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Viatris Inc's Revenue has grown by 29.14%, rising from $11.95B to $15.43B. For next year, analysts predict Revenue of $16.51B, which would mean an increase of 7.00%. Over the next seven years, experts predict that Viatris Inc's Revenue will grow at a rate of 10.85%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$414.47 | Buy/Sell | $457.59 | 8.57% |
REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$964.44 | Buy/Sell | $961.26 | 8.87% |
ZTS Stock Forecast | Zoetis | Outperform |
18
|
$183.49 | Buy/Sell | $220.47 | 20.72% |
Viatris Inc Dividend per Share Forecast for 2023 - 2025 - 2030
In the last year, Viatris Inc's Dividend per Share has grown by 6.67%, rising from $0.45 to $0.48. For next year, analysts predict Dividend per Share of $0.58, which would mean an increase of 20.83%. In 2030, professionals predict that Viatris Inc's Dividend per Share will decrease by 17.52%, to $0.40.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$43.48 | Buy/Sell | $44.86 | 3.50% |
ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$149.10 | Buy/Sell | $245.24 | 44.20% |
UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$249.51 | Buy/Sell | $284.08 | 19.63% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
CTLT Stock Forecast | Catalent | Hold |
15
|
$56.81 | Buy/Sell | $49.29 | 11.78% |
CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$64.39 | Buy/Sell | $87.92 | 45.99% |
IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$43.26 | Buy/Sell | $55.60 | 41.01% |
Viatris Inc EBITDA Forecast for 2023 - 2025 - 2030
Viatris Inc's EBITDA has grown In the last three years, rising from $2.66B to $3.67B – a growth of 38.07%. In the next year, analysts believe that EBITDA will reach $5.95B – an increase of 61.95%. For the next seven years, experts predict that Viatris Inc's EBITDA will grow at a rate of 95.74%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$260.15 | Buy/Sell | $315.92 | 29.16% |
BCPC Stock Forecast | Balchem | Outperform |
18
|
$156.04 | Buy/Sell | $145.00 | 4.46% |
NEOG Stock Forecast | Neogen | Outperform |
16
|
$16.19 | Buy/Sell | $37.00 | 17.36% |
Viatris Inc EBIT Forecast for 2023 - 2025 - 2030
Viatris Inc's EBIT has seen impressive growth In the last three years, rising from $764.40M to $877.80M – a growth of 14.84%. In the next year, analysts believe that EBIT will reach $5.54B – an increase of 531.05%. For the next seven years, the forecast is for EBIT to grow by 620.63%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$43.81 | Buy/Sell | $69.00 | 41.52% |
TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$16.37 | Buy/Sell | $29.44 | 107.70% |
CORT Stock Forecast | Corcept Therapeutics | Buy |
16
|
$23.75 | Buy/Sell | $35.67 | 60.00% |
Viatris Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Viatris Inc's EPS has fallen from $3.95 to $0.00 – a 100.00% decrease. For next year, analysts predict EPS of $3.44, which would mean an increase of 100.00%. Over the next seven years, experts predict that Viatris Inc's EPS will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
INDV Stock Forecast | Indivior PLC | Buy |
14
|
£16.50 | Buy/Sell | £28.89 | 92.00% |
IRWD Stock Forecast | Ironwood Pharmaceuticals | Buy |
14
|
$8.95 | Buy/Sell | $17.83 | 95.53% |
CPRX Stock Forecast | Catalyst Pharmaceuticals | Buy |
16
|
$16.10 | Buy/Sell | $26.20 | 58.39% |